Highlights Corcept Therapeutics Incorporated

Equities

CORT

US2183521028

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-14 pm EDT			5-day change	1st Jan Change
28.97 ^USD	-8.06%		-13.03%	-10.81%

Jun. 14	Global markets live: Tesco, Adobe, Tyson Foods, GameStop, Teva...
Jun. 14	Teva Pharmaceutical Sues Corcept Therapeutics Alleging Market Monopolization for Cushing's Syndrome Drug Korlym	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Global markets live: Tesco, Adobe, Tyson Foods, GameStop, Teva...	Jun. 14
Teva Pharmaceutical Sues Corcept Therapeutics Alleging Market Monopolization for Cushing's Syndrome Drug Korlym	Jun. 14	MT
Teva sues Corcept over mifepristone 'monopoly' for rare disorder	Jun. 13	RE
Sector Update: Health Care Stocks Retreat Tuesday Afternoon	May. 28	MT
Corcept Therapeutics Says Phase 3 Hypercortisolism Trial Meets Primary Endpoint; Shares Advance	May. 28	MT
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 Grace Trial of Relacorilant in Patients with Hypercortisolism (Cushing?S Syndrome)	May. 28	CI
Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Reports Q1 EPS $0.25, vs. Street Est of $0.22	May. 01	MT
Corcept Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
Corcept Therapeutics Incorporated Completes Enrollment in Phase 4 Catalyst Trial	Apr. 29	CI
Corcept Therapeutics Incorporated Announces Positive Results from Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients with Cushing?s Syndrome	Apr. 22	CI
Corcept Completes Enrollment in Phase 2 Dazals Trial in Patients with Amyotrophic Lateral Sclerosis	Apr. 15	CI
Corcept Therapeutics Incorporated Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer	Apr. 08	CI
Corcept Therapeutics Incorporated Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients with Adrenal Cushing's Syndrome	Apr. 01	CI
Corcept Therapeutics Q4 Net Income, Revenue Increase; Reiterates Guidance; Shares Gain Pre-Bell	Feb. 16	MT
Corcept Therapeutics Q4 Net Income, Revenue Increase; Reiterates Guidance	Feb. 15	MT
Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2024	Feb. 15	CI
Corcept Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Corcept Therapeutics Incorporated Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Corcept Therapeutics Incorporated Announces Preliminary Results from Prevalence Phase of CATALYST Clinical Trial	Feb. 15	CI
Corcept Therapeutics Sees 31% Increase in Q4 Revenue, Issues 2024 Revenue Guidance	Jan. 08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Corcept Therapeutics Incorporated

Equities

CORT

US2183521028

Highlights

Filters